Mechanism of action: Solifenacin balliculeVisual mnemonic: Solifenacin mascot “Solar fencin’ Vesica cares” “red as a beet” → anticholinergic asterisk → no mad hatter hat → minimal CNS effects due to minimal blood-brain barrier penetration
What it isM3-preferring muscarinic antagonist; overactive bladder.
Why this oneThe antimuscarinic specifically labeled with mirabegron when either mechanism alone is inadequate.
What limits itStill anticholinergic, so cognition and constipation matter in the elderly. QT prolongation; CYP3A4 substrate.
Molecular structure: Solifenacin
Solifenacin prescription history
Animated chart of estimated U.S. prescriptions per year, Overactive bladder meds (1970–2026). Solifenacin enters in 2005 (estimated).
FDA-approved for
overactive bladder (2004)
Principal riskAnticholinergic burden and QT prolongation
Defining liabilityGenerally tolerated at therapeutic doses; clinically important risks are agent-specific and increase with interactions or organ impairment.